Ambrosia Biosciences
Biotech · Healthcare
Ambrosia Biosciences Secures $100M Series B for Oral GLP-1 Push
March 31, 2026$100M · Series B
Ambrosia Biosciences raised $100M in an oversubscribed Series B to advance its oral small-molecule GLP-1 therapy into Phase 1 trials. Co-led by Blue Owl Healthcare Opportunities, Redmile Group, and Deep Track Capital.
Lead Investors
Blue OwlRedmile GroupDeep Track Capital
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.